.webp)
Agentic AI
Sponsors talk AI: Sanofi's take on the evolving role of AI in clinical trials
Artificial intelligence continues to move from experimentation to execution across the life sciences industry. On a recent episode of the AI in Business podcast, Matthew Peruhakal, Global Head of Data Architecture, Utilization, and AI Engineering at Sanofi, offered a deep look at how the pharmaceutical giant is integrating AI to transform clinical trials. From intelligent data workflows to proactive risk detection and regulatory alignment, Peruhakal described an organization reshaping its research and development operations around a new digital core.
His message was clear: AI cannot remain a side project. To make a meaningful impact, it must be embedded as a strategic capability that connects people, systems, and data across the enterprise.
Sponsors talk AI: Novartis’ take on the evolving role of AI in clinical trials
Artificial intelligence is shifting from promise to practice in biopharma, and few domains feel the impact more than clinical development. In a recent conversation on the AI in Business podcast, Zhong Lu, director of data science and AI at Novartis, outlined how AI is evolving the clinical trials process end to end. His perspective centered on building internal platforms that unite structured and unstructured data, deploying document intelligence to remove process friction, and using responsible generative AI to support scientific decision making without compromising compliance. While the regulatory bar remains high and patient trust is paramount, Novartis’s approach shows how targeted applications of AI can streamline data operations, strengthen regulatory readiness, and make both traditional and decentralized trials faster and more resilient.
Building blocks: The ultimate guide to AI in clinical trials
Explore how artificial intelligence (AI) is fundamentally transforming every facet of clinical trials, from initial protocol design and patient recruitment to data management and regulatory approval. This comprehensive guide provides an authoritative, in-depth look at AI's role in accelerating drug development and improving patient outcomes, with special focus on emerging agentic AI technologies.
Eliminate clinical trial white space with the right AI strategy
It has become clear that our industry has reachedthe limits of human-only clinical development. As clinical trials have become increasingly complex, the endeavors that people alone can perform are no longer sufficient to generate the momentum needed to address the growing burden of human disease. This has led to longer drug development timelines and significant delays for patients. One large are of lost time is “white space,” definied simply as unproductive time caused by manual, sequential processes and fragmented data systems. Thankfully, a solution lies in agentic AI and its abilities to perform series of tasks.
Building blocks: Agentic AI is Transforming trial design, management, and outcomes
Discover how Agentic AI is revolutionizing clinical trials by optimizing efficiency, accelerating drug development, and improving patient access to therapies.
An overview of Agent Studio
Agent Studio reimagines the clinical trial lifecycle, automating slow, manual processes, removing barriers in the clinical process, and introducing new ways to achieve clinical goals like never before. This first-of-its-kind, AI-powered, no-code platform lets you deploy ready-to-go agents trained as clinical development experts or create bespoke ones using your own data and expertise, unlocking endless possibilities.
Rewriting the Future of Clinical Trials: AI, Agility, and the Portfolio-First Mandate
In a rapidly changing research landscape, leaders at Takeda, Novartis, Sanofi, Daiichi Sankyo, and Medable share firsthand insights into how artificial intelligence is reshaping clinical trial operations.
This exclusive whitepaper explores how forward-thinking organizations are reimagining trial design, execution, and scaling to meet the demands of speed, precision, and patient-centricity across their entire portfolio.